11.17.21

Matt Posard Joins Vizgen Board of Directors

Single-cell spatial genomics instrument pioneer appoints genomics commercialization expert

CAMBRIDGE, Mass. November 17, 2021–(BUSINESS WIRE)–Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announces the appointment of Matt Posard to their Board of Directors. As the first outside director for Vizgen, Matt will provide guidance to expand market strategies and corporate growth.

A seasoned executive in the genomics and life science space, Matt has an extensive background in launching novel and transformational products, generating high revenue growth, and effectively scaling organizations. Matt held executive positions at Illumina for almost 10 years including global marketing and sales during its first $1B in annual revenue. Matt also served as Senior VP and General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units and was responsible for a notable $100M+ of sales growth in his first year as SVP/GM. Presently, Matt is leading Explore DNA as Founding Principal and serves on many boards for both public and private companies in the life sciences, diagnostics, and therapeutics arena.

“Matt joins our board with an impressive 30 years of commercial and general management expertise in the life sciences industry, combined with a remarkable history of success,” said Terry Lo, President and CEO of Vizgen. “His deep knowledge and background of the genomics market will help advance our mission to bring spatial genomics and our MERSCOPETM platform to researchers around the world.”

“I am deeply honored to be joining Vizgen’s Board of Directors,” says Matt. “The cutting-edge technology offered by Vizgen’s MERSCOPE platform opens an incredible opportunity within the emerging single-cell spatial genomics market, and I look forward to being a part of it. It’s an exciting time for this highly specialized and accomplished team.”